A Study of ARRY-334543 and Gemcitabine in Patients With Advanced Cancer and Pancreatic Cancer
Status:
Completed
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
This is a 2-phase study during which patients with advanced/metastatic solid tumors will
receive investigational study drug ARRY-334543 and gemcitabine.
The study has 2 parts. In the first part of the study, Phase 1, patients with
advanced/metastatic solid tumors will receive increasing doses of study drug in combination
with gemcitabine in order to achieve the highest dose of study drug possible that will not
cause unacceptable side effects. Patients will be followed to see what side effects the
combination causes and what effectiveness the combination has, if any, in treating the
cancer. Approximately 24 patients from the US will be enrolled in Part 1 (Completed).
In the second part of the study, Phase 2, patients with metastatic pancreatic cancer will
receive the best dose of study drug, in combination with gemcitabine, determined from the
first part of the study and will be followed to see what side effects the combination causes
and what effectiveness the combination has, if any, in treating the cancer. Approximately 42
patients from the US will be enrolled in Part 2 (Withdrawn).